Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2000-Year of the Biotechs! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (186)	2/6/2000 5:51:00 AM
From: Cheryl Galt	Respond to of 1142

Torben, >hope that when it settles, intellectual property retains >some decent monetary respect >IP is hard to value and it doesn't fit well with present accounting methods. The investing public has been willing to reward Amazon, has understood that -- despite growing losses, quarter after quarter --Amazon is building a fortress-like POSITION for making future profits. Some biotechs, likewise, are well positioned -- because of their IP, well-chosen targets, and savvy management. If they can reach critical mass before they run out of funding, they will be unstoppable. imo The positioning of some biotechs is analogous to Amazon-style positioning. If more investors learn to discern the real values from the hyped plays, promising biotechs will have the fair stock prices they need -- for access to the funding needed to attain critical mass. If the rally ends (I hope) with the solid-IP, well-managed companies at a fair level, investors are ahead -- long-term much more ahead than possible with momo profits. I cringe to see momo money being wasted on scams -- enriching some gamblers, impoverishing others. Want that money to pour into promising companies, that will leverage it. We shall see ...